Oxford
BioDynamics
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
Issue of shares in lieu of
salary,
Director / PDMR shareholdings
& Total voting rights
Oxford, UK - 28 October
2024 - Oxford BioDynamics,
Plc (AIM: OBD, the Company), a precision
clinical diagnostics company bringing specific and sensitive tests
to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform, announces the issue of
2,285,741 ordinary shares of 1 pence each ("Ordinary Shares") at a
price of 1.3 per share (the "New Ordinary Shares") to its
directors, PDMRs and certain other senior staff members to satisfy
part of their salaries and fees, in line with the Company's ongoing
strategy to preserve its cash resources as announced on 14 October
2024. The issue price is equal to the closing market price of the
Company's Ordinary Shares on 25 October 2024, being the last
practicable date prior to the issue of the New Ordinary
Shares.
The New Ordinary Shares being issued
have been allocated to the following directors and
PDMRs:
|
Director / PDMR
|
Position
|
Number of New Ordinary Shares
issued
|
Resultant shareholding in the
Company
|
% of the issued share capital
of the Company
|
|
Dr Jon Burrows
|
Chief Executive Officer
|
492,682
|
1,581,570
|
0.50
|
|
Dr Alexandre Akoulitchev
|
Chief Scientific Officer
|
194,263
|
7,130,678
|
2.27
|
|
Paul Stockdale
|
Chief Financial Officer
|
179,847
|
678,331
|
0.22
|
|
Matthew Wakefield
|
Non-Executive Chairman
|
98,118
|
1,398,622
|
0.45
|
|
Dr David Holbrook
|
Non-Executive Director
|
49,653
|
49,653
|
0.02
|
|
Thomas Guiel
|
Chief Operating Officer
|
184,545
|
808,433
|
0.26
|
|
Dr Ewan Hunter
|
Chief Data Officer
|
164,763
|
356,681
|
0.11
|
Application will be made for the New
Ordinary Shares to be admitted to trading on AIM ("Admission") and
it is expected that Admission will occur at 8.00 a.m. on or around
1 November 2024. The New Ordinary Shares have been issued as fully
paid and rank pari passu in all respects with the existing Ordinary
Shares.
Following Admission, the Company's
issued share capital will consist of 314,141,391 Ordinary Shares.
There are no shares held in treasury. Therefore, the Company's
total number of Ordinary Shares in issue and voting rights will be
314,141,391 and this figure may be used by Shareholders from
Admission as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Further details of the PDMR dealings
are included below. This information has been provided in
accordance with Article 5(1)(b) of the Market Abuse Regulation (EU)
No 596/2014 which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018.
-Ends-
For
more information:
|
Oxford BioDynamics
Plc
Jon Burrows, CEO
Paul Stockdale, CFO
|
+44
(0)1865 518910
|
|
Shore Capital
(Nominated Adviser and Broker to OBD)
Stephane Auton
Lucy Bowden
|
+44 (0)20
7408 4090
|
|
WG
Partners
(Joint Broker to
OBD)
David Wilson / Claes Spång /
Satheesh Nadarajah / Erland Sternby
|
+44
(0)20 3705 9330
|
|
Vigo
Consulting
(Media / Analyst enquiries
for OBD)
Rozi Morris
|
+44 (0)20
7390 0230
obd@vigoconsulting.com
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is
an international biotechnology company, advancing personalized
healthcare by developing and commercializing precision clinical
diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products:
the
EpiSwitch® PSE (EpiSwitch
Prostate Screening test) and
EpiSwitch® CiRT (Checkpoint
Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or
absence of prostate cancer. CiRT is a
highly accurate (85%) predictive response test to immuno-oncology
checkpoint inhibitor treatments.
The tests are based on OBD's
proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring
of biomarkers to diagnose patients or determine how individuals
might respond to a disease or treatment.
OBD's clinical smart tests have the
potential to be used across a broader range of indications, and new
tests are being developed in the areas of oncology, neurology,
inflammation, hepatology and animal health.
The Group's headquarters and UK
laboratories are in Oxford, UK. Its US operations and clinical
laboratory are in Maryland, USA, along with a reference laboratory
in Penang, Malaysia.
OBD is listed on the London Stock
Exchange's AIM (LSE: OBD). For more information, please visit the
Company's website,
www.oxfordbiodynamics.com,
X (@OxBioDynamics) or
LinkedIn.
The notifications below, made in
accordance with the requirements of the UK Market Abuse Regulation,
provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
1) Dr Jon
Burrows
2) Dr Alexandre
Akoulitchev
3) Paul
Stockdale
4) Matthew
Wakefield
5) Dr David
Holbrook
6) Thomas
Guiel
7) Dr Ewan
Hunter
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
1) Chief Executive
Officer, Director
2) Chief
Scientific Officer, Director
3) Chief Financial
Officer, Director
4) Non-Executive
Director
5) Non-Executive
Director
6) Chief Operating
Officer, PDMR
7) Chief Data Officer, PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Oxford Biodynamics plc
|
|
b)
|
LEI
|
2138005Y1TK258O5U928
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares
ISIN: GB00BD5H8572
|
|
b)
|
Nature of the transaction
|
Issue of New Ordinary Shares in lieu
of salary
|
|
c)
|
Price(s) and volume(s)
|
|
|
Price(s)
|
Volume(s)
|
|
1)
|
1.3p
|
492,682
|
|
2)
|
1.3p
|
194,263
|
|
3)
|
1.3p
|
179,847
|
|
4)
|
1.3p
|
98,118
|
|
5)
|
1.3p
|
49,653
|
|
6)
|
1.3p
|
184,545
|
|
7)
|
1.3p
|
164,763
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A - single transactions
|
|
e)
|
Date of the transaction
|
28 October 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
